Bijuva

Amenorrhea, hormonal imbalance, prophylaxis of recurrent spontaneous preterm birth + 9 more

Treatment

20 Active Studies for Bijuva

What is Bijuva

Progesterone

The Generic name of this drug

Treatment Summary

Estradiol is a hormone produced naturally in female bodies. It is available in various forms as a hormone therapy to treat conditions caused by low estrogen levels, such as hot flashes and vaginal dryness. It can be taken orally as a pill, injected, used as a vaginal ring, patch, spray, gel, or cream. When taken orally or by injection, it is usually combined with a pro-drug ester. Ethinyl estradiol is a synthetic version of estradiol that is commonly used in combination with other hormones in birth control pills. It is more effective than estradiol because it is more bioavailable and

Progesterone

is the brand name

image of different drug pills on a surface

Bijuva Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Progesterone

Progesterone

1978

124

Effectiveness

How Bijuva Affects Patients

Estradiol is used to treat hot flashes, vaginal dryness, and other urogenital symptoms. It can also help increase bone density, improve the levels of certain proteins and hormones in the blood, and reduce the amount of follicle-stimulating hormones. However, it can increase the risk of developing cardiovascular disease, blood clots, and stroke. It also causes a hyper-coagulable state and can lead to increased levels of sodium in the body, which can cause hypertension.

How Bijuva works in the body

Estrogen is naturally produced in the ovaries of adult women. After menopause, the majority of estrogen is created in the body from androstenedione, a hormone produced by the adrenal cortex. Estrogen works by binding to two types of receptors, ERα and ERβ, as well as GPER, which helps control its rapid effects. Once bound, estrogen enters the cell's nucleus and changes gene expression, which leads to the relief of postmenopausal symptoms like hot flashes, chills, sleep problems, and more.

When to interrupt dosage

The recommended measure of Bijuva is contingent upon the recognized condition, including Premature Menopause, Pharmaceutical Preparations and Postmenopause. The dosage fluctuates in line with the administration method depicted in the table beneath.

Condition

Dosage

Administration

recurrent spontaneous preterm birth

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Reproductive Technology

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Endometrial Hyperplasia

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Amenorrhea

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

hormonal imbalance

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Postmenopause

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Hysterectomy

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Amenorrhea

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Uterine hemorrhage

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Vasomotor System

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Hot flashes

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

prophylaxis of recurrent spontaneous preterm birth

50.0 mg, , 50.0 mg/mL, 100.0 mg, 200.0 mg, 0.09 mg/mg, 0.045 mg/mg, 8.0 %, 10.0 mg/mL, 17.0 mg/mL, 0.001 mg/mg, 1.1 mg/hour, 25.0 mg/mL, 1.0 mg/mg, 0.0025 mg/mg

Injection - Intramuscular, Injection, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Capsule - Oral, Capsule, Oral, Gel, Vaginal, Gel - Vaginal, Insert - Vaginal, Insert, Liquid - Intramuscular, Liquid, Solution - Intramuscular, Solution, Oral; Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule - Vaginal, Cream - Vaginal, Cream, Cream - Topical, Topical, Solution - Topical, Ring - Vaginal, Ring, Capsule; Spray, metered - Oral; Transdermal, Capsule; Spray, metered, Subcutaneous, Solution - Subcutaneous, Cream - Transdermal, Transdermal

Warnings

Bijuva Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thromboembolism

Do Not Combine

suspected pregnancy

Do Not Combine

Pulmonary Embolism

Do Not Combine

Stroke

Do Not Combine

Cerebrovascular accident

Do Not Combine

Thrombophlebitis

Do Not Combine

Breast

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Pulmonary Embolism

Do Not Combine

Pulmonary Embolism

Do Not Combine

Breast Cancer

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Breast

Do Not Combine

Breast

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

suspected pregnancy

Do Not Combine

Thromboembolism

Do Not Combine

Malignant Neoplasms

Do Not Combine

Stroke

Do Not Combine

undiagnosed vaginal bleeding

Do Not Combine

Abortion, Spontaneous

Do Not Combine

Venous Thrombosis

Do Not Combine

Thrombophlebitis

Do Not Combine

Stroke

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Progesterone may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Progesterone may interact with Pulse Frequency

There are 20 known major drug interactions with Bijuva.

Common Bijuva Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Progesterone.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Progesterone.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Progesterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Progesterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Progesterone.

Bijuva Toxicity & Overdose Risk

Tests have shown that taking a small amount of estradiol every day over a 90 day period has no adverse effects. However, taking too much estradiol can lead to nausea, vomiting, abdominal pain, breast tenderness, blood clots, and vaginal bleeding. If someone has taken too much estradiol, it is recommended to stop taking it and provide supportive care.

image of a doctor in a lab doing drug, clinical research

Bijuva Novel Uses: Which Conditions Have a Clinical Trial Featuring Bijuva?

Currently, 867 active clinical trials are assessing the potential of Bijuva to address Osteoporosis, Amenorrhea of 6 months or longer duration and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Endometrial Hyperplasia

0 Actively Recruiting

Postmenopause

5 Actively Recruiting

Phase 2, Not Applicable

recurrent spontaneous preterm birth

0 Actively Recruiting

Uterine hemorrhage

0 Actively Recruiting

hormonal imbalance

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Amenorrhea

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Reproductive Technology

2 Actively Recruiting

Not Applicable

Amenorrhea

0 Actively Recruiting

prophylaxis of recurrent spontaneous preterm birth

0 Actively Recruiting

Hysterectomy

3 Actively Recruiting

Phase 3, Not Applicable

Bijuva Reviews: What are patients saying about Bijuva?

5

Patient Review

9/11/2020

Bijuva for "Change of Life" Signs

I've been taking Bijuva for just under a year now and it's really helped.

5

Patient Review

9/30/2020

Bijuva for "Change of Life" Signs

I'm really pleased with this medication.

5

Patient Review

6/20/2021

Bijuva for "Change of Life" Signs

I've tried two different treatments and had bad reactions to both of them. I was willing to put up with it because they were working so well, but my doctor suggested Bijuvia and it's been a week with no negative side effects so far.

5

Patient Review

7/20/2020

Bijuva for "Change of Life" Signs

I just started taking Bijuva and it's fantastic.

5

Patient Review

1/11/2021

Bijuva for "Change of Life" Signs

This treatment is really effective. I was amazed at how well it worked and how quickly I felt better.

4.7

Patient Review

8/4/2020

Bijuva for "Change of Life" Signs

Bijuva helped me get rid of my hot flashes and sleep better. I also saw an improvement in my sex life. However, after taking it for about 5 months, I've gained 15 pounds.

4.3

Patient Review

2/14/2022

Bijuva for "Change of Life" Signs

The night sweats have disappeared, sleeping well but I have gained 8lbs in two months. I need to find a solution without gaining weight.

3

Patient Review

9/30/2021

Bijuva for "Change of Life" Signs

I'm experiencing a lot of unpleasant side effects from this medication, including leg cramps, kidney and back pain, acne, and emotional outbursts. It's like going through PMS all over again. I hope the hot flashes stop soon.

2.3

Patient Review

8/18/2020

Bijuva for "Change of Life" Signs

I experienced a 14 pound weight gain by the second packet. I have always been lucky and not had trouble with controlling my weight. Also, fatigue was an issue too. It did however stop the night sweats but unfortunately was not a good fit for me.

2.3

Patient Review

8/5/2020

Bijuva for "Change of Life" Signs

When I first started taking bijuva, I felt great. My mood was better and I didn't have any vaginal dryness.

2

Patient Review

11/9/2022

Bijuva for "Change of Life" Signs

I strongly advise against this medication if you have a history of depression. It exacerbated my condition to the point where I was suicidal. Once I stopped taking it, however, I felt better within days. Additionally, it also caused me pain in my gallbladder.

2

Patient Review

9/14/2022

Bijuva for "Change of Life" Signs

I had high hopes for this medication, but unfortunately it has not helped me sleep better at all. In fact, I feel bloated and have gained several pounds since starting to take it a month ago.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bijuva

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Bijuva a bioidentical hormone?

"Bijuva contains estradiol and progesterone that are chemically identical to the hormones that women produce naturally."

Answered by AI

Does Bijuva make you gain weight?

"Since Bijuva contains the hormones estradiol (a form of estrogen) and progesterone, it's possible that you may experience weight gain as a side effect of Bijuva. If you're concerned about weight gain or weight loss while taking Bijuva, talk with your doctor to see if this is a normal side effect or something to be concerned about."

Answered by AI

What are the benefits of taking Bijuva?

"1 capsule of BIJUVA once a day can help with moderate to severe hot flashes by replacing the estrogen your body loses during menopause. A study showed that BIJUVA can reduce the frequency and severity of moderate to severe hot flashes in menopausal women."

Answered by AI

Clinical Trials for Bijuva

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of Shady Grove Fertility Rockville in Rockville, United States.

ICSI vs IVF for Female Infertility

Any Age
Female
Rockville, MD

The goal of this clinical trial is to learn whether two different methods of helping eggs and sperm join-intracytoplasmic sperm injection (ICSI) and conventional in vitro fertilization (IVF)-lead to better embryo development when using frozen donor sperm in people who do not have male fertility problems. The main questions it aims to answer are: Does one method create more usable embryos (blastocysts) than the other? Is there a difference in how often fertilization does not happen at all? Do either of the methods lead to better embryo quality or early pregnancy? Participants will: Have their eggs divided into two groups. One group will be fertilized using ICSI (where a sperm is injected directly into an egg), and the other using conventional IVF (where eggs are mixed with sperm in a dish). The fertilization method for each egg will be randomly assigned, with a random process also used to determine the assignment of any extra egg when an odd number is collected. Continue regular fertility treatment while the study team compares the results of each fertilization method. This study includes people with non-male factor infertility and uses frozen donor sperm. It hopes to learn whether ICSI, which is often used even when it may not be needed, truly helps improve outcomes compared to conventional IVF in these cases.

Recruiting
Has No Placebo

Shady Grove Fertility Rockville

Kate Devine, MD

Have you considered Bijuva clinical trials?

We made a collection of clinical trials featuring Bijuva, we think they might fit your search criteria.
Go to Trials
Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR

The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks

Recruiting
Has No Placebo

Don tyson Center for Agricultural Sciencers (+1 Sites)

Jamie Baum

Have you considered Bijuva clinical trials?

We made a collection of clinical trials featuring Bijuva, we think they might fit your search criteria.
Go to Trials
Image of The Buck Institute for Research on Aging in Novato, United States.

GLYLO Supplement for Postmenopausal Aging

45 - 65
Female
Novato, CA

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Recruiting
Advanced

The Buck Institute for Research on Aging

Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Image of Cedars Sinai Medical Center in Los Angeles, United States.

Family Foundations for Pregnancy

18+
Female
Los Angeles, CA

The purpose of this study is to help expectant single mothers build a coparenting bond and improve communication with a support person (co-caregiver). Participation will include completing two online surveys (one at 12-30 weeks gestation \& one at 3 months postpartum), providing two at-home bloodspot collections and return via mail. Studies suggest that stress increases inflammation. Investigators aim to explore this by collecting a small amount of blood at the first and last session; attending 9 virtual one-two hour Family Foundations (FF) intervention sessions (at no cost to participants) with a supportive co-caregiver (total time commitment will be 18 hours, max, over a 6 month period).

Recruiting
Has No Placebo

Cedars Sinai Medical Center

Have you considered Bijuva clinical trials?

We made a collection of clinical trials featuring Bijuva, we think they might fit your search criteria.
Go to Trials